[go: up one dir, main page]

CL2022003660A1 - Vesículas extracelulares con inmunomoduladores. - Google Patents

Vesículas extracelulares con inmunomoduladores.

Info

Publication number
CL2022003660A1
CL2022003660A1 CL2022003660A CL2022003660A CL2022003660A1 CL 2022003660 A1 CL2022003660 A1 CL 2022003660A1 CL 2022003660 A CL2022003660 A CL 2022003660A CL 2022003660 A CL2022003660 A CL 2022003660A CL 2022003660 A1 CL2022003660 A1 CL 2022003660A1
Authority
CL
Chile
Prior art keywords
extracellular vesicles
immunomodulators
evs
aav
methods
Prior art date
Application number
CL2022003660A
Other languages
English (en)
Inventor
Winslow Genine
Original Assignee
Chameleon Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chameleon Biosciences Inc filed Critical Chameleon Biosciences Inc
Publication of CL2022003660A1 publication Critical patent/CL2022003660A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70532—B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/577—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 tolerising response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Transplantation (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Dispersion Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

En la presente se proporcionan vesículas extracelulares (EV) que comprenden una bicapa lipídica que comprende una o más moléculas inmunosupresoras. También se proporcionan en la presente métodos para inducir tolerancia a un agente terapéutico tal como AAV, usando las EV descritas en la presente.
CL2022003660A 2020-06-24 2022-12-20 Vesículas extracelulares con inmunomoduladores. CL2022003660A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202063043587P 2020-06-24 2020-06-24

Publications (1)

Publication Number Publication Date
CL2022003660A1 true CL2022003660A1 (es) 2023-08-04

Family

ID=77022213

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2022003660A CL2022003660A1 (es) 2020-06-24 2022-12-20 Vesículas extracelulares con inmunomoduladores.

Country Status (12)

Country Link
US (1) US20230355803A1 (es)
EP (1) EP4171596A1 (es)
JP (1) JP2023531721A (es)
KR (1) KR20230049618A (es)
CN (1) CN116322725A (es)
AU (1) AU2021297242A1 (es)
BR (1) BR112022026309A2 (es)
CA (1) CA3187321A1 (es)
CL (1) CL2022003660A1 (es)
IL (1) IL299299A (es)
MX (1) MX2022016224A (es)
WO (1) WO2021262879A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12453743B2 (en) 2018-05-30 2025-10-28 Direct Biologics, Llc Mesenchymal stem cell (MSC) growth factor and extracellular vesicle preparation in frozen or powdered form and methods of use
EP3999083A4 (en) 2019-07-18 2023-07-26 Direct Biologics LLC Preparations comprising mesenchymal stem cells and cannabinoids and methods of their use
WO2025212859A1 (en) * 2024-04-03 2025-10-09 Solid Biosciences, Inc. Methods and constructs for increasing solid organ transplant survival

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011106376A2 (en) 2010-02-23 2011-09-01 The General Hospital Corporation Use of microvesicles in the treatment of medical conditions
WO2015048566A1 (en) 2013-09-26 2015-04-02 The General Hospital Corporation Methods of isolating extracellular vesicles
US20200392219A1 (en) 2017-05-08 2020-12-17 Trustees Of Tufts College Extracellular vesicles comprising membrane-tethered tgf-beta, compositions and methods of use thereof
WO2019027847A1 (en) 2017-07-29 2019-02-07 University Of Southern California SYNTHETIC EXTRACELLULAR VESICLES FOR NEW THERAPIES
AU2018394238A1 (en) 2017-12-28 2020-06-18 Lonza Sales Ag Exosomes for immuno-oncology and anti-inflammatory therapy
MX2020007390A (es) * 2018-01-11 2020-10-14 Chameleon Biosciences Inc Vectores immunoevasivos y uso para terapia genica.
JP7378413B2 (ja) 2018-03-12 2023-11-13 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム イムノエキソソームおよびその使用方法
WO2020257710A1 (en) 2019-06-21 2020-12-24 Entelexo Biotherapeutics Inc. Platforms, compositions, and methods for therapeutics delivery
WO2021003445A1 (en) 2019-07-03 2021-01-07 Codiak Biosciences, Inc. Extracellular vesicles targeting t cells and uses thereof

Also Published As

Publication number Publication date
CA3187321A1 (en) 2021-12-30
CN116322725A (zh) 2023-06-23
MX2022016224A (es) 2023-02-23
US20230355803A1 (en) 2023-11-09
EP4171596A1 (en) 2023-05-03
AU2021297242A1 (en) 2023-02-09
IL299299A (en) 2023-02-01
KR20230049618A (ko) 2023-04-13
JP2023531721A (ja) 2023-07-25
BR112022026309A2 (pt) 2023-01-17
WO2021262879A1 (en) 2021-12-30

Similar Documents

Publication Publication Date Title
CL2022003660A1 (es) Vesículas extracelulares con inmunomoduladores.
MX2022001770A (es) Vesícula extracelular unida a moléculas y usos de esta.
CL2020002055A1 (es) Macrociclos como moduladores del regulador de conductncia transmembrana de la fibrosis quística, composiciones farmacéuticas de estos, su uso en el tratamiento de la fibrosis quística y procesos para elaborarlos.
CO2020009091A2 (es) Exosomas para inmunooncología y terapia antiinflamatoria
CO2022015170A2 (es) Composiciones que comprenden una variante del polipéptido cas12i2 y usos de las mismas
CL2021001027A1 (es) Inhibidores selectivos de rgmc y el uso de los mismos
ECSP19028690A (es) Modulador del regulador de conductancia de transmembrana de fibrosis quística, composiciones farmacéuticas, y proceso para producir el modulador
GT201700167A (es) Terapias de combinación para el tratamiento de cánceres.
UY36554A (es) ARNi VARIANTE
DOP2020000135A (es) Composiciones de péptidos tau fosforilados y sus usos
CL2020002915A1 (es) Composiciones para el tratamiento de condiciones de la piel
PE20160030A1 (es) COMPOSICIONES DE ARNi DE SERPINA 1 Y SUS METODOS DE USO
MX2018005829A (es) Composiciones para tratar el cabello.
PE20181139A1 (es) Composiciones y metodos para inhibir la expresion genica de lpa
MX2019002338A (es) Formulaciones de anticuerpos inhibidores de masp-2 altamente concentradas de baja viscosidad, kits, y metodos.
MX2016009428A (es) Proteinas de union a calicreina en plasma y usos de las mismas para tratar el angioedema hereditario.
CL2015002462A1 (es) Polímero conjugado para entregar un agente bioactivo
CL2019000787A1 (es) Métodos para tratar trastornos mitocondriales y metabólicos.
UY38797A (es) Anticuerpos inmunomoduladores y métodos de uso de los mismos
ECSP20000655A (es) AGENTES DE iARN PARA LA INHIBICIÓN DE LA EXPRESIÓN DE ALFA-ENaC Y MÉTODOS DE USO
MX2021001722A (es) Composiciones que comprenden vesiculas derivadas de celulas y usos de las mismas.
CO7141430A2 (es) Formulaciones vesiculares para uso en el tratamiento del dolor o movilidad reducida de una articulación
MX370928B (es) El uso de 9-cis-retinil acetato para mejorar la función visual de un sujeto que padece de pérdida de la función visual originada por una deficiencia retinoide endógena de 11-cis retinal.
CO2023013243A2 (es) Agentes de rnai para inhibir la expresión del receptor para productos finales de glicación avanzada, composiciones de estos y métodos de uso
CL2025000194A1 (es) Construcciones de arni para inhibir expresión de scap y sus usos